Cart
sales@molnova.com
Ezabenlimab
CAS No. 2249882-54-8
Ezabenlimab( —— )
Catalog No. M36792 CAS No. 2249882-54-8
Ezabenlimab (BI-754091) is an anti-PD-1 monoclonal antibody (mAb) with a binding constant (Kd) of 6 nM in CHO cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 490 | In Stock |
|
| 10MG | 787 | In Stock |
|
| 25MG | 1169 | In Stock |
|
| 50MG | 1535 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEzabenlimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEzabenlimab (BI-754091) is an anti-PD-1 monoclonal antibody (mAb) with a binding constant (Kd) of 6 nM in CHO cells.
-
DescriptionEzabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo.
-
In VitroEzabenlimab inhibits the interaction of PD-1 to PD-L1 and PD-L2 in CHO cells with IC90s of 4.14 nM and 3.98 nM, respectively; and inhibits the interaction of PD-1 to PD-L1 and PD-L2 in cynomolgus with IC90s of 5.61 nM and 7.54 nM, respectively.Ezabenlimab increases IFN-γ secretion in primary human antigen-experienced CD3-positive T cells, with an EC50 value of 0.9 nM.Ezabenlimab (200 nM) has synergistic effect with BI 754111, resulting in further increase of IFN-γ secretion.
-
In VivoEzabenlimab (0.3-30 mg/kg; i.p.; single dose or twice per week or every 3 weeks) inhibits tumor progress and shows comparable anti-tumor activity in hPD-1 knock-in mouse model.Animal Model:hPD-1 knock-in mouse model Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg Administration:Intraperitoneal injection; single dose or twice per week or every 3 weeks Result:Showed tumor growth inhibition (TGI) at day 25 dose-dependently of 99%, 101%, 91%, 48%, and 44%, respectively.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2249882-54-8
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zettl M, et al. Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. Oncoimmunology. 2022 Jun 16;11(1):2080328. ?
molnova catalog
related products
-
Justicidin A
Justicidin A is a type of bioactive chemical from Justica procumbens.
-
Lobaplatin (D-19466)
Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexes. Lobaplatin (D-19466) shows activity for a variety of tumour types and is a promising antitumour chemotherapeutic agent.
-
Orexin A (human, rat...
Endogenous agonist at orexin receptors (Ki values are 20 and 38 nM for OX1 and OX2 receptors respectively). Stimulates feeding following central administration and may be involved in the control of sleep-wake cycle and other hypothalamic functions.
